Literature DB >> 30125379

Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study.

Kaveh Hajifathalian1, Babak Torabi Sagvand2, Arthur J McCullough3,4,5.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) comprises more than two thirds of patients with chronic liver disease in the United States. The effect of alcohol consumption on survival in patients with NAFLD is not clear. We gathered data on National Health and Nutrition Examination Survey participants from 1988 to 2010, and linked them to the National Death Index for follow-up of their survival. We diagnosed NAFLD based on a previously validated biochemical model (Hepatic Steatosis Index). We built multivariate Cox proportional hazards models to evaluate the effect of alcohol consumption on survival of patients with NAFLD. After excluding participants with significant alcohol use, viral hepatitis, or increased transferrin saturation, 4,568 participants with NAFLD were included in the analysis. In a Cox model adjusted for age, sex, and smoking history, drinking 0.5-1.5 drinks per day decreased the risk of overall mortality by 41% (hazard ratio [HR] = 0.59, 95% confidence interval [CI] 0.40-0.85, P = 0.005) compared with not drinking. Drinking ≥1.5 drinks per day showed a trend toward harm (HR = 1.16, 95% CI 0.99-1.36, P = 0.119). After further adjustment for race, physical activity, education level, diabetes, and fiber and polyunsaturated fatty acid intake, drinking 0.5-1.5 drinks per day continued to show a significant protective effect (HR = 0.64, 95% CI 0.42-0.97, P = 0.035), and drinking ≥1.5 drinks per day showed a significant harmful effect on mortality (HR = 1.45, 95% CI 1.01-2.10, P = 0.047). Among patients with NAFLD, modest alcohol consumption is associated with a significant decrease in all-cause mortality, whereas drinking ≥1.5 drinks per day is associated with an increase in mortality. These results help to inform the discussion of potential risks and benefits of alcohol use in patients with NAFLD.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 30125379      PMCID: PMC6380949          DOI: 10.1002/hep.30226

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  50 in total

1.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

2.  Roles of alcohol consumption in fatty liver: a longitudinal study.

Authors:  Akio Moriya; Yoshiaki Iwasaki; Souhei Ohguchi; Eizo Kayashima; Tadahiko Mitsumune; Hideaki Taniguchi; Masaharu Ando; Kazuhide Yamamoto
Journal:  J Hepatol       Date:  2014-11-27       Impact factor: 25.083

3.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Authors:  Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison
Journal:  Gastroenterology       Date:  2010-09-19       Impact factor: 22.682

4.  Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

Authors:  Cecilia Söderberg; Per Stål; Johan Askling; Hans Glaumann; Greger Lindberg; Joel Marmur; Rolf Hultcrantz
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

5.  Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease.

Authors:  M de Lorgeril; S Renaud; N Mamelle; P Salen; J L Martin; I Monjaud; J Guidollet; P Touboul; J Delaye
Journal:  Lancet       Date:  1994-06-11       Impact factor: 79.321

6.  Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study.

Authors:  Peter Jepsen; Hendrik Vilstrup; Lene Mellemkjaer; Ane Marie Thulstrup; Jørgen H Olsen; John A Baron; Henrik Toft Sørensen
Journal:  Hepatogastroenterology       Date:  2003 Nov-Dec

7.  Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest.

Authors:  D S Siscovick; T E Raghunathan; I King; S Weinmann; K G Wicklund; J Albright; V Bovbjerg; P Arbogast; H Smith; L H Kushi
Journal:  JAMA       Date:  1995-11-01       Impact factor: 56.272

8.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Amy G Shah; Alison Lydecker; Karen Murray; Brent N Tetri; Melissa J Contos; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2009-06-10       Impact factor: 11.382

9.  Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies.

Authors:  Mark A Pereira; Eilis O'Reilly; Katarina Augustsson; Gary E Fraser; Uri Goldbourt; Berit L Heitmann; Goran Hallmans; Paul Knekt; Simin Liu; Pirjo Pietinen; Donna Spiegelman; June Stevens; Jarmo Virtamo; Walter C Willett; Alberto Ascherio
Journal:  Arch Intern Med       Date:  2004-02-23

10.  Alcohol consumption and risk of fatty liver disease: a meta-analysis.

Authors:  Guoli Cao; Tingzhuang Yi; Qianqian Liu; Min Wang; Shaohui Tang
Journal:  PeerJ       Date:  2016-10-27       Impact factor: 2.984

View more
  17 in total

1.  Alcohol consumption in non-alcoholic fatty liver disease-harmful or beneficial?

Authors:  Stergios Kechagias; Julia Blomdahl; Mattias Ekstedt
Journal:  Hepatobiliary Surg Nutr       Date:  2019-06       Impact factor: 7.293

2.  Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016.

Authors:  Donghee Kim; Won Kim; Adeyinka C Adejumo; George Cholankeril; Sean P Tighe; Robert J Wong; Stevan A Gonzalez; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Hepatol Int       Date:  2019-01-29       Impact factor: 6.047

3.  Racial Disparities in Associations of Alcohol Consumption With Liver Disease Mortality in a Predominantly Low-Income Population: A Report From the Southern Community Cohort Study.

Authors:  Lei Fan; Xiangzhu Zhu; Alexandra Shingina; Edmond K Kabagambe; Martha J Shrubsole; Qi Dai
Journal:  Am J Gastroenterol       Date:  2022-04-13       Impact factor: 12.045

4.  Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Lisa B VanWagner; Hongyan Ning; Norrina B Allen; Veeral Ajmera; Cora E Lewis; John Jeffrey Carr; Donald M Lloyd-Jones; Norah A Terrault; Juned Siddique
Journal:  Gastroenterology       Date:  2017-08-09       Impact factor: 33.883

Review 5.  Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?

Authors:  Maria L Petroni; Lucia Brodosi; Francesca Marchignoli; Alessandra Musio; Giulio Marchesini
Journal:  Nutrients       Date:  2019-12-13       Impact factor: 5.717

Review 6.  Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered.

Authors:  Maria Corina Plaz Torres; Alessio Aghemo; Ana Lleo; Giorgia Bodini; Manuele Furnari; Elisa Marabotto; Luca Miele; Edoardo G Giannini
Journal:  Nutrients       Date:  2019-12-05       Impact factor: 5.717

Review 7.  Role of ALDH2 in Hepatic Disorders: Gene Polymorphism and Disease Pathogenesis.

Authors:  Qiaoling Wang; Binxia Chang; Xiaoyan Li; Zhengsheng Zou
Journal:  J Clin Transl Hepatol       Date:  2021-01-04

8.  Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.

Authors:  Kushala W M Abeysekera; Gwen S Fernandes; Gemma Hammerton; Andrew J Portal; Fiona H Gordon; Jon Heron; Matthew Hickman
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-01-15

Review 9.  Aldehyde Dehydrogenase, Liver Disease and Cancer.

Authors:  Wenjun Wang; Chunguang Wang; Hongxin Xu; Yanhang Gao
Journal:  Int J Biol Sci       Date:  2020-01-22       Impact factor: 6.580

10.  Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake.

Authors:  Seonghwan Hwang; Tianyi Ren; Bin Gao
Journal:  Clin Mol Hepatol       Date:  2020-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.